-
Investor Relations
- Corporate Governance
- Investor Presentations
- Annual Reports
- Compliance and AML
- Sustainability
- Financial Information
- Shareholders Toolkit
- FAQs
- Investors’ Queries
-
-
-
Accounts
- Al Hayrat Account
- Current Account
- Fixed Deposits Account
- Money Maker Account
- Salary Transfer Account
- Starmaker Account
- Super Saver Account
-
Al Wajaha
- Overview
-
BBK Lite
- Overview
-
NRI
- NRI Services
-
Debit Cards
- Classic
- Gold
- Signature
- Infinite
-
Self-service Banking
- ATM
- Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
- Debit Card Issuance Machines
-
Foreign Exchange
- Remittance
- American Express
-
-
-
Insurance
- Home Secura
- Motor Secura
- Travel Secura
-
Investment
- Bonds
- IPO
- Mutual Funds
- Real Estate Investment
-
-
-
Branches and Self-Service
- Branches
- ATM
- Deposit Machines
- Debit Card Issuance Machines
- Corporate Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
-
Contactless Payments
- Apple Pay
- Samsung Wallet
- Google Pay
- Garmin Pay
- Fitbit Pay
-
More Ways to Bank
- Mobile app & Online Banking
- eStatements
- BBK BanKey
- Corporate Deposit Card
- Debit Card
- Telebanking
- Open Banking
- AFAQ Payment System
- Remittance
- Visa Click to Pay
-
Sign Language
- Sign Language Directory
-
-
-
-
-
Accounts
- Business Current Account
- Business Fixed Deposit Account
-
Cash Management
- Bankey eBanking
- Payroll Services
- Deposit Machines
- POS Credimax
- Remittance
-
-
-
Working Capital Finance
- Overdraft
- Cheque discounting
- Short Term Loans
-
Long Term Finance
- Project Finance
- Assets Finance
- Real estate Finance
-
-
-
Corporate Banking
- Government Affairs
- Real Estate, Services and Trading
- Contracting, Building Material, and Manufacturing
-
International Banking
- Overview
- Services
- NRI
- Offshore Branches
- Representative offices
-
Enterprise Banking
- Overview
-
-
-
-
-
FINANCIAL NEWS
Jordan’s Hikma faces lower full-year revenue
11 Nov 2016
(MENAFN) Hikma Pharmaceuticals Plc reduced its full-year revenue predictions for its generics business, due to slower ramp-up in the unit.Moreover, the firm bought U.S generic drugs business this year, proclaimed that its now predict full-year revenue from the business to reach USD600mn.Accordingly, it also said that it predicted full-year core operating profit from its generics unit to be hurt by a delay in approval of new products.In addition, the firm predicts full-year revenue to grow by 35 percent to almost USD2bn in constant currency.
More News
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
26 Jan 2026
BBK Enhances Autumn Fair 2026 Experience with Customized Rewards and Premium Services
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more